Lancet Microbe最新文献

{"title":"Diagnostics and therapeutics: the CRISPR story continues","authors":"The Lancet Microbe","doi":"10.1016/j.lanmic.2026.101417","DOIUrl":"10.1016/j.lanmic.2026.101417","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101417"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147636813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards the endgame: achieving elimination of viral hepatitis in England","authors":"Sema Mandal , Philippa C Matthews , Monica Desai , Matthew Hickman","doi":"10.1016/j.lanmic.2025.101332","DOIUrl":"10.1016/j.lanmic.2025.101332","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101332"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145946551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection study","authors":"Hans de Graaf PhD , Diane F Gbesemete PhD , Alison R Hill PhD , Janeri Fröberg PhD , Muktar M Ibrahim PhD , Adam P Dale PhD , Jay R Laver PhD , Prof Andrew R Gorringe PhD , Prof Saul N Faust FRCPCH , Kent E Kester MD , Annemarie M Buisman PhD , Prof Guy A M Berbers PhD , Jolanda Brummelman PhD , Prof Cecile A C M van Els PhD , Marc J Eleveld BSc , Dimitri A Diavatopoulos PhD , Robert C Read MD","doi":"10.1016/j.lanmic.2025.101313","DOIUrl":"10.1016/j.lanmic.2025.101313","url":null,"abstract":"<div><h3>Background</h3><div>Cyclical epidemics of pertussis, also known as whooping cough, continue to occur despite vaccination, because current vaccines fail to suppress colonisation by, and transmission of, the causative agent <em>Bordetella pertussis</em>. We aimed to show the safety of <em>B pertussis</em> controlled human infection delivered in an outpatient setting, as well as identify immunological correlates of protection against <em>B pertussis</em> colonisation, to guide the future development of pertussis vaccines.</div></div><div><h3>Methods</h3><div>This open-label, phase 1, controlled human infection study was conducted at University Hospital Southampton, Southampton, UK. Healthy volunteers aged 18–55 years who had received a whole-cell pertussis vaccine in childhood were inoculated intranasally with 10<sup>5</sup> colony-forming units of wild-type <em>B pertussis</em> strain B1917. Volunteers were monitored as outpatients for 28 days to assess safety, colonisation, and <em>B pertussis-</em>specific immunological parameters. Individuals who shared a bedroom with inoculated volunteers were enrolled to measure transmission to close contacts. After approximately 90 days, volunteers who agreed to participate in a rechallenge phase of the study were re-inoculated with the same dose of <em>B pertussis</em>. Volunteers received azithromycin 14 days after each inoculation. The primary objective was to assess the safety of delivering this controlled human infection model on an outpatient basis; safety endpoints were the occurrence of possible or confirmed pertussis and unsolicited or serious adverse events. Secondary objectives were the assessment of immunological biomarkers of protection from colonisation and the assessment of transmission from volunteers to close contacts. All volunteers who received the inoculum were included in the safety analysis, and all participants who completed follow-up to day 14 were included in the per-protocol population for colonisation and immunological analysis. This trial is registered at <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, <span><span>NCT03751514</span><svg><path></path></svg></span>, and is ongoing.</div></div><div><h3>Findings</h3><div>Between Aug 29, 2019 and March 6, 2023, 77 volunteers were screened and 51 were enrolled and inoculated, of whom 50 completed follow-up to day 14 post-inoculation. 20 (40%) of these 50 volunteers became colonised with <em>B pertussis</em>. One volunteer developed symptoms suggestive of possible pertussis after initial inoculation; this volunteer tested negative for <em>B pertussis</em> throughout the study and all symptoms resolved within 4 days. Adverse events were mostly mild to moderate, with no significant increase in the reporting of any individual symptom by colonised volunteers. All unsolicited adverse events were assessed as either unlikely to be related or unrelated to <em>B pertussis</em> infection, with no increase in the frequ","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101313"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refocusing syphilis vaccine research on preventing vertical transmission","authors":"Joseph D Tucker , Chido Dziva Chikwari , Lisa Frigati , Linda Grillová , Pingyu Zhou","doi":"10.1016/j.lanmic.2025.101327","DOIUrl":"10.1016/j.lanmic.2025.101327","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101327"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145805943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lineage dynamics of invasive Escherichia coli isolates in the Netherlands from 1975 to 2021: a retrospective longitudinal genomic analysis","authors":"Ann E Snaith PhD ,&nbsp;Boas van der Putten PhD ,&nbsp;Wendy Bril-Keijzers BSc ,&nbsp;Rebecca J Hall PhD ,&nbsp;Steven J Dunn PhD ,&nbsp;Prof Willem van Schaik PhD ,&nbsp;Prof Nina M van Sorge PhD ,&nbsp;Prof Alan McNally PhD","doi":"10.1016/j.lanmic.2025.101300","DOIUrl":"10.1016/j.lanmic.2025.101300","url":null,"abstract":"<div><h3>Background</h3><div><em>Escherichia coli</em> is a common cause of invasive infections such as bloodstream and cerebrospinal fluid infections in neonates. Strains positive for the K1 capsule are considered the most common cause of such neonatal invasive infections. This assumption of K1 dominance, and indeed the population genomics of <em>E coli</em> causing invasive infections in general is largely unstudied. We aimed to provide a comprehensive characterisation of this pathogen population using a longitudinal isolate collection.</div></div><div><h3>Methods</h3><div>In this analysis we report the findings of the SENTINEL study, a longitudinal genomic analysis of 1790 invasive <em>E coli</em> isolates collected mainly from newborns in the Netherlands between 1975 and 2021 by the Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam University Medical Centre, Amsterdam, Netherlands. The dataset included all bacterial strains cultured from cerebrospinal fluid or blood in cases of (clinical) bacterial meningitis (1976 to 1980). In 1981 the criteria were expanded to include neonates (aged ≤4 weeks) with <em>E coli</em> sepsis, and from July, 2016 all infants younger than 1 year with <em>E coli</em> sepsis were included. All isolates were sequenced using either the HiSeq 2500 or HiSeq 4000 platforms (Illumina, San Diego, CA, USA). We confirmed species and identified sequence types (STs), detected antimicrobial resistance genes, virulence genes, and the presence of K1 capsule, and characterised the dynamics of these factors over time.</div></div><div><h3>Findings</h3><div>Our data show a highly dynamic bacterial population that is entirely unaffected by antimicrobial resistance determinants. Key pathogen population fluctuations include the complete disappearance of the dominant lineage ST567 and the swapping of dominant ST95 clones from a single serotype O18:H7 clone to two distinct serotype O1:H7 clones, with changes in virulence factors including major fimbrial adhesins. These findings, combined with only 58·8% (1053 of 1790) prevalence in K1-expressing isolates in the entire study population, point to host–pathogen interaction and immune selection pressures as key drivers of bacterial population dynamics in this largely antimicrobial-naive population.</div></div><div><h3>Interpretation</h3><div>Our data show the vital need for ongoing genomic surveillance of microbial pathogen populations to guide appropriate intervention strategies. Additionally, genomic insights of a pathogen population from one specific disease syndrome or patient population cannot always be generalised across other cohorts.</div></div><div><h3>Funding</h3><div>Wellcome Antimicrobial and Antimicrobial Resistance Doctoral Training Programme and the National Institute for Health and Care Research Birmingham Biomedical Research Centre.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101300"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaginal microbiota transplantation for treatment of vaginal dysbiosis without the use of antibiotics: a double-blind, randomised controlled trial in women with vaginal dysbiosis","authors":"Tine Wrønding PhD ,&nbsp;Kilian Vomstein DrMedHabil ,&nbsp;Agnete Troen Lundgaard PhD ,&nbsp;Kevin DeLong PhD ,&nbsp;Sarah Mollerup PhD ,&nbsp;Brynjulf Mortensen PhD ,&nbsp;Elleke F Bosma PhD ,&nbsp;Ann Marie Hellerung MSc ,&nbsp;Emilie Vester Engel MD ,&nbsp;Klara Dortea Wiil MD ,&nbsp;Julie Elm Heintz MSc ,&nbsp;Sofie Ingdam Halkjær PhD ,&nbsp;Luisa W Hugerth PhD ,&nbsp;Tanja Schlaikjær Hartwig PhD ,&nbsp;Prof Andreas Munk Petersen DMSc ,&nbsp;Anne Bloch Thomsen PhD ,&nbsp;David Westergaard PhD ,&nbsp;Nina la Cour Freiesleben PhD ,&nbsp;Prof Henrik Westh DMSc ,&nbsp;Johan E T van Hylckama Vlieg PhD ,&nbsp;Henriette Svarre Nielsen DMSc","doi":"10.1016/j.lanmic.2025.101294","DOIUrl":"10.1016/j.lanmic.2025.101294","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;A vaginal microbiota dominated by &lt;em&gt;Lactobacillus&lt;/em&gt; species is associated with reduced risk of infection and adverse reproductive outcomes. Effective interventions to restore healthy microbiota remain scarce. In this study, we aimed to assess the efficacy of vaginal microbiota transplants (VMTs) without antibiotic pretreatment in achieving conversion to a &lt;em&gt;Lactobacillus&lt;/em&gt;-dominated vaginal microbiome.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This single-centre, double-blind, randomised controlled trial was done at Copenhagen University Hospital (Hvidovre, Denmark) between June 1, 2021, and March 1, 2023. We enrolled women aged 18–40 years with asymptomatic or symptomatic molecular vaginal dysbiosis (&lt;10% total relative abundance of &lt;em&gt;Lactobacillus&lt;/em&gt; spp and &gt;20% relative abundance of &lt;em&gt;Gardnerella&lt;/em&gt; spp, &lt;em&gt;Fannyhessea vaginae&lt;/em&gt;, and &lt;em&gt;Prevotella&lt;/em&gt; spp) who were otherwise healthy premenopausal women and not pregnant as recipients; donors were healthy women aged 18–40 years with a &lt;em&gt;Lactobacillus&lt;/em&gt;-dominated vaginal microbiota (&gt;80%) and a low (&lt;5%) abundance of &lt;em&gt;Gardnerella&lt;/em&gt; spp, &lt;em&gt;F vaginae&lt;/em&gt;, and &lt;em&gt;Prevotella&lt;/em&gt; spp, and negative screening for sexually transmitted infections. Participants were randomly assigned (3:1) to the intervention or placebo through a computer-generated schedule with block randomisation and stratification by hormonal contraception. Participants and investigators were masked to the group. Up to three administrations of VMT or placebo were given across three menstrual cycles, with follow-up for six cycles. The primary endpoint was resolution of dysbiosis at any timepoint during follow-up, defined as at least 70% relative abundance of &lt;em&gt;Lactobacillus&lt;/em&gt; spp and less than 10% combined abundance of &lt;em&gt;Gardnerella&lt;/em&gt; spp, &lt;em&gt;F vaginae&lt;/em&gt;, and &lt;em&gt;Prevotella&lt;/em&gt; spp, as assessed by shotgun metagenomic sequencing of vaginal samples. This analysis was done in the intention-to-treat population, excluding any participants who withdrew consent. An extension study assessed the effect of antiseptic pretreatment before additional VMT in refractory participants. This study was registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;NCT04855006&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;) and is completed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;A total of 302 women were screened, of whom 49 were enrolled. 37 women were randomly assigned to the VMT group (mean age 26·1 years [SD 3·8]) and 12 to the placebo group (27·3 years [4·8]). The primary outcome showed no significant difference in dysbiosis resolution between active and placebo groups (HR 0·65; 95% CI 0·20–2·16, p=0·49). In an extension study of refractory participants, five (50%) of the ten women who received antiseptic pretreatment followed by VMT had a microbiome conversion. Adverse events occurred in 15 (42%) VMT participants and five (42%) placebo","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101294"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147575860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiological peristaltic-like reactions of the tracheobronchial tree move pulmonary Mycobacterium tuberculosis bacilli into the gastrointestinal tract","authors":"Andrew R DiNardo ,&nbsp;George W Kasule ,&nbsp;Alberto L Garcia-Basteiro ,&nbsp;Stool4TB Global Partnership","doi":"10.1016/j.lanmic.2025.101275","DOIUrl":"10.1016/j.lanmic.2025.101275","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101275"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147636798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating microbiomes into One Health: insights from the 2025 One Health World Microbiome Partnership Summit","authors":"","doi":"10.1016/j.lanmic.2025.101319","DOIUrl":"10.1016/j.lanmic.2025.101319","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101319"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, recovery, and pharmacodynamics of CRISPR–Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study","authors":"Anders Østergaard Petersen PhD ,&nbsp;Birgitte Damholt PhD ,&nbsp;Mette Grove PhD ,&nbsp;Jonas Hink PhD ,&nbsp;Tamara Marotte-Hurbon MSc ,&nbsp;Johan Söderqvist MSc ,&nbsp;Alice Troy PhD ,&nbsp;Milan Zdravkovic MD ,&nbsp;Lone Bayer ,&nbsp;Katja Brunner PhD ,&nbsp;Tina Bryde ,&nbsp;Jasper Clube MSc ,&nbsp;Yilmaz Emre Gencay PhD ,&nbsp;Aurelie Gram DVM ,&nbsp;Jakob Krause Haaber PhD ,&nbsp;Björn Hallström PhD ,&nbsp;Džiuginta Jasinskytė PhD ,&nbsp;Ricardo Pascal ,&nbsp;Marianne Petersen ,&nbsp;Szabolcs Semsey PhD ,&nbsp;Christian Grøndahl Med (Dr)","doi":"10.1016/j.lanmic.2025.101257","DOIUrl":"10.1016/j.lanmic.2025.101257","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Patients with haematological cancer who receive stem-cell transplantation are at risk of bloodstream infections, often caused by multidrug resistant gut pathogens such as &lt;em&gt;Escherichia coli&lt;/em&gt;. SNIPR001 is a cocktail of four CRISPR–Cas-armed bacteriophages that reduce colonisation of &lt;em&gt;E coli&lt;/em&gt; in the gastrointestinal tract in animal models and is designed to not affect other members of the commensal microbiota. We aimed to investigate the safety and tolerability of SNIPR001 in healthy participants.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this randomised, placebo-controlled, double-blind, first-in-human, dose-escalation trial conducted at a single centre (Medpace Clinical Pharmacology Unit; Cincinnati, OH, USA), we sequentially enrolled healthy participants (aged 18–65 years) with more than 10&lt;sup&gt;7&lt;/sup&gt; &lt;em&gt;E coli&lt;/em&gt; colony-forming units per gram of stool into cohorts 1, 2, and 3, pending a safety review of the previous enrolment group where applicable. Participants in each cohort were randomly assigned to treatment or placebo using a unique three-digit participant identification number. Participants were orally administered 10&lt;sup&gt;8&lt;/sup&gt; plaque-forming units (PFU) per dose (cohort 1), 10&lt;sup&gt;10&lt;/sup&gt; PFU per dose (cohort 2), and 10&lt;sup&gt;12&lt;/sup&gt; PFU per dose (cohort 3) of SNIPR001 or placebo (phosphate-buffered saline buffer), twice daily for 7 days. All personnel, except for a pharmacy staff member who prepared both SNIPR001 and placebo vials, were masked to the administered dose and assignment; masking was ensured by fully covering the surface of each vial. Participants were followed up to day 187. The primary outcome was the incidence and severity of adverse events and medically attended adverse events from the first administration of the study drug until 4 weeks after the last dose administration on day 35 of the study. Recovery and biodistribution of SNIPR001 in faeces, blood, and urine; pharmacodynamics, including the ability of SNIPR001 to reduce &lt;em&gt;E coli&lt;/em&gt; levels in stool (assessed using a linear mixed-effects model); and microbiome composition (using Bray–Curtis dissimilarity) were secondary outcomes. Primary safety analyses were assessed per-protocol (ie, all enrolled participants who received at least one administration of the study drug). This trial was conducted under an Investigational New Drug application from the US Food and Drug Administration, is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;NCT05277350&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;), and is closed to new participants.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;The trial was carried out between March 24, 2022, and Nov 30, 2022. 36 eligible participants were randomly assigned to receive SNIPR001 or placebo in cohorts 1 (six assigned to 10&lt;sup&gt;8&lt;/sup&gt; PFU per dose and two assigned to placebo), 2 (six to 10&lt;sup&gt;10&lt;/sup&gt; PFU per dose and two to placebo), and 3 (12 to 10&lt;sup&gt;12&lt;/sup","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101257"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147366872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human metapneumovirus prevention within reach: advances in vaccines and monoclonal antibodies","authors":"Heng Li PhD ,&nbsp;Jianhong Zhang PhD ,&nbsp;Kang Wang PhD ,&nbsp;Prof Sergio Bernardini PhD ,&nbsp;Hong Zhang PhD ,&nbsp;Prof Yang Luo MD PhD","doi":"10.1016/j.lanmic.2025.101303","DOIUrl":"10.1016/j.lanmic.2025.101303","url":null,"abstract":"<div><div>Human metapneumovirus (HMPV) is a major respiratory pathogen that commonly causes mild to moderate upper respiratory tract infections in infants, with only a subset progressing to severe lower respiratory disease globally, particularly in older adults (aged ≥60 years) and individuals with compromised immunity. Efforts to develop an HMPV vaccine or immunoprophylaxis are still ongoing. The rapid advancements in understanding the virus’s structure, particularly the surface proteins involved in immune evasion and viral fusion, have paved the way for promising vaccine-based and antibody-based interventions. The range now encompasses multiple vaccine candidates and monoclonal antibodies undergoing clinical trials; in particular, vaccines using different platforms such as virus-like particle-based, live attenuated, epitope-based, mRNA-based, vector-based, and plant-based approaches, in addition to monoclonal antibodies aimed at preventing or reducing disease severity. This Review emphasises innovative strategies for HMPV vaccine design and offers a detailed overview of HMPV vaccine candidates that are currently in clinical development, aimed at preventing a prevalent and severe infectious disease affecting young children (aged &lt;5 years) and older adults globally.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 4","pages":"Article 101303"},"PeriodicalIF":20.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}